Evidence map›Paper›PMID 42707638›Full record

ReviewTheranostics2026

Frailty and [

Matteo Bauckneht, Nicolò Borsellino, Giuseppe Ferdinando Colloca, Lucia Fratino, Daniele Santini

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Matteo BaucknehtDepartment of Health Sciences (DISSAL), University of Genova, Genova, Italy.
Nicolò BorsellinoMedical Oncology Unit, Ospedale Buccheri La Ferla Fatebenefratelli, Palermo, Italy.
Giuseppe Ferdinando CollocaDepartment of Geriatrics, Orthopaedics and Rheumatology, Fondazione A Gemelli IRCCS, Rome, Italy.
Lucia FratinoMedical Oncology Unit, IRCCS Centro Di Riferimento Oncologico di Aviano, Aviano, Italy.
Daniele SantiniDepartment of Sciences and Medical-surgical Biotechnologies, UOC Oncologia, Policlinico Umberto 1, La Sapienza Università di Roma, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prognosis of metastatic castration-resistant prostate cancer is dismal. [

Indexed as

DipeptidesHeterocyclic Compounds, 1-RingLutetiumProstatic Neoplasms, Castration-ResistantRadioisotopesAgedFrail ElderlyHumansMaleNeoplasm MetastasisProstate-Specific AntigenDipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177Prostate-Specific AntigenPSMA-617Radioisotopes

Identifiers

PMID42707638
PMCPMC13549133

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.